The infiltration of the synovial membrane (SM) by mononuclear cells, mostly T cells, is a typical histopathological feature associated with rheumatoid arthritis (RA). The entry of T lymphocytes into the SM is believed to be mediated by a number of molecules in the endothelium that are induced in response to a series of inflammatory mediators. In this study, we have investigated the adhesion of synovial T cells from RA patients to two endothelial ligands: endothelial-leukocyte adhesion molecule-i (ELAM-1), the only selectin known to function as a vascular addressin for T cells, and vascular cell adhesion molecule-i (VCAM-1), the cellular ligand of VLA4. Our results clearly demonstrate that synovial T cells isolated from both SM and synovial fluid (SF), bearing an activated and memory phenotype, displayed an enhanced capacity to interact with these two endothelial molecules as compared with T cells from peripheral blood (PB) either of the same RA patients or healthy donors. A further enhancement of VLA4-mediated T cell binding to VCAM-1 and fibronectin could be observed when already in vivo-activated synovial T cells were stimulated in vitro with phorbol esters, suggesting the existence of several cellular affinity levels for both very late activation4 (VLA4) ligands. Moreover, both PB and synovial T cells from RA patients exhibited strong proliferative responses when they were cultured with either fibronectin or VCAM-1 in combination with submitogenic doses of anti-CD3 mAb. This increased endothelial binding ability of synovial T lymphocytes together with their proliferation in response to the interaction with VCAM-1 and fibronectin may represent important mechanisms in the regulation of T cell penetration and persistence in the chronically inflamed SM
Introduction
RA constitutes one of the paradigms of chronic inflammatory processes in humans. T cells emigrating from peripheral blood (PB)' and infiltrating the RA synovial membrane (SM) are believed to play an important role in the pathogenesis of the disease (1) (2) (3) (4) . The entry of PB T lymphocytes to the SM requires, as a first step, the binding of T cells to the endothelium (reviewed in refs. 2 and 3). A wide array ofadhesion molecules has been described to be involved in this interaction (5) (6) (7) (8) . Recent reports indicate that the initial leukocyte interaction with endothelium is mediated by CD62 (PADGEM/GMP 140) and endothelial-leukocyte adhesion molecule-1 (ELAM-1) molecules that belong to a newly described group of structurally related cell adhesion receptors, termed selectins (9) (10) (11) (12) (13) (14) , which also include the MEL-14/LAM-1 homing receptor (15) . In myeloid cells, certain carbohydrate determinants, Lewis X and sialylated Lewis x epitopes, have been described as ligands for CD62 and ELAM-l (16) (17) (18) (19) (20) . A T cell subset has been demonstrated to bind to the endothelial ELAM-1 molecule; however, the T cell counter receptor for this selectin remains unidentified (21) (22) (23) .
Once the leukocyte selectin-mediated binding to endothelial cells (EC) has taken place, the leukocyte integrins and their counter receptors in EC participate in the subsequent shear-resistant attachment to endothelium, and in the penetration into the inflammed tissue (1 1-14) . Integrins, comprising a group of a: heterodimers involved in both cell-cell contacts and cell-extracellular matrix (ECM) interactions (7, 8) , have also been implicated in lymphocyte binding to endothelium. While lymphocyte function associated antigen-l (LFA-1) interacts with ICAM-1 and ICAM-2 (24) (25) (26) , very late antigen-4 (VLA-4) integrin binds to other endothelial ligand known as vascular cell adhesion molecule-1 (VCAM-1)/inducible cell adhesion molecule 110 (INCAM-l 10) (27, 28) . VLA-4 is the only integrin that, in addition to its involvement in leukocyte-endothelial adhesion, has also been implicated in the attachment to the ECM component fibronectin (FN) (29, 30) .
The pathogenesis of RA lesions remains controversial. Some reports show the increment of an activated circulating T cell population in RA (31) (32) (33) (34) (35) (36) (37) .
In this study, we have investigated the binding ofT lymphocytes isolated from the three compartments (peripheral blood, synovial membrane, and synovial fluid [SF] ) of RA patients to two adhesion molecules specifically expressed by activated endothelial cells: ELAM-l and VCAM-1. Our results show an upregulated T cell adhesiveness to both EC ligands, as well as an increased attachment to FN. The significance of these phenomena are discussed in the context of the RA pathogenesis.
Methods
Patients. 13 patients diagnosed as having RA according to American College of Rheumatology criteria (38) were studied. SF and PB were collected from all of them. Synovial tissue was obtained during synovectomy in two of these RA patients undergoing knee surgery. Their mean age was 55.1 yr (ranging from 30 to 60 yr), and the duration of disease ranged from 2 mo to 40 yr, with a mean of 12 yr of evolution. Four patients were taking nonsteroidal antinflammatory drugs, four were on prednisone (< 20 mg/d), two patients were treated with methotrexate, three were treated with gold salts, one with antimalarial compounds, and one with D-penicillamine.
Monoclonal antibodies. CD3 SPV-T3b mAb was kindly provided by Dr. De Vries (UNICET Labs, Dardilly, France) (39) . HP2/1 is directed against a4 chain of VLA-4 (40) . TS2/16 mAb recognizes the (B1 common chain of VLA family, and was previously characterized (41) . Anti-VCAM-I 4B9 mAb (42) was the generous gift ofDr. Harlan (University of Washington, Seattle, WA). BB1 1 mAb recognizes ELAM-1, as previously described (43) . TPI/55 and TP1/8 mAb, recognizing AIM/CD69, and D3/9 mAb, directed against CD45, were obtained in our laboratory (44, 45 Cell attachment assays. Recombinant soluble VCAM-l (rsVCAM-1) and ELAM-1 (rsELAM-l) were purified by immunoaffinity chromatography from conditioned medium of Chinese hamster ovary (CHO) cells stably transfected with a truncated cDNA for VCAM-1 and ELAM-l, respectively (23,48). A 38-kD proteolytic fibronectin (FN38) fragment was kindly supplied by Dr. A. Garcia-Pardo (Centro de Investigaciones Biol gicas, CSIC, Madrid), and obtained as described (29) . Type I collagen was purchased from Sigma Chemical Co.
Adhesion assays were performed as previously described (37 try analysis on either PB or SF T cells (data not shown), indicating that these glycosylated epitopes, present on myeloid cells (18, 19) , are not incriminated in the observed T cell interactions with ELAM-1. Most synovial T cells from rheumatoid arthritis patients bind to VCAM-J. The expression of VCAM-1 has been detected on EC, synovial macrophages, and in the lining layer macrophages of RA synovial tissue (50) (51) . Very recently, in vitro activation has been described to induce a strong enhancement in T cell binding to VCAM-1 (52). Moreover, a higher expression of both VLA-4 chains, as well as some activation antigens (CD69/AIM, HLA-DR), could be noticed in synovial T cells isolated from both SM and SF, as compared with PB (Table I) . Therefore, we explored the binding of in vivo-activated synovial T cells from RA patients, as well as their PB T cells, to rsVCAM-1. The majority of synovial T cells from both SF and SM were able to bind to rsVCAM-1, in contrast to the low binding typical for PB T lymphocytes from those patients, as well as healthy donors (Fig. 3) . The differential capacity of SF and PB RA T cells in adhesion to rsVCAM-1 could be evidenced in Fig. 2, C (29) , could be further upregulated by in vitro activation. As expected, treatment for 30 min with phorbol esters or crosslinked CD3 mAb enhances PB T cell adhesiveness to both VLA-4 ligands (Fig. 4) . By contrast, no significant enhancement in SF T cell binding to VCAM-l and FN38 was observed upon PMA and CD3 treatment (Fig. 4) . The lack of a further regulation of SF T cell binding to VCAM-1 and FN38 by in vitro stimulation could be due to their constitutive in vivo-activated state, making them unresponsive to an additional stimulus. Alternatively, one could argue that the ligand concentrations used in this study were high enough to completely saturate their receptors, thus allowing for maximal binding reactions. If this were the case, then one would not detect differences on binding probably reflecting the existence of multiple levels of cellular affinity for FN38 and VCAM-1. To clarify this point, we assayed PMAtreated and untreated synovial and PB T cells for binding to FN38 and rsVCAM-1 applied at different doses. As illustrated in Fig. 5 , an increase in cell attachment of PMA-treated versus untreated SF T lymphocytes was observed at FN38 and rsVCAM-1 concentrations below 15 ,ug/ml and 1 ,ug/ml, respectively. Thus, in vivo-activated SF T cells exhibited a higher capacity than PB T cells to interact with both VLA-4 ligands, but in vitro activation increased the adhesiveness even more, PB and SF T cells (Table II) . FN38 also increased the proliferation of CD3-treated T cells, although in a lower extent than VCAM-1, which is in agreement with previous reports demonstrating that VLA-5 is the major FN receptor implicated in T cell proliferation triggered by this ECM protein (55) (56) (57) (58) . Neither rsVCAM-l nor FN38 induced comitogenic effects in combination with PMA, although this phorbol ester showed to be strongly comitogenic with anti-CD69 TPI/8 mAb (data not shown).
Discussion
The results reported herewith demonstrate that synovial T cells from RA patients exhibit a higher capacity to interact with VCAM-1, as compared with PB T cells from the same patients. Furthermore, synovial T cells show an enhanced binding, about twofold, to ELAM-1 which could probably reflect the activity of a T cell subset. The increased adhesiveness of synovial T cells to their endothelial ligands can thus reflect pathologic phenomena occurring in the inflamed tissue of patients with RA, and, therefore, extend our current understanding of the pathophysiology ofthis disease. Although the patients stud- ied were receiving different therapies, the pattern of adhesive reactivity observed was very similar in all of them, which strongly suggests that the observed phenomena were related to disease itself, and not their treatment, age, duration, and evolution ofthe disease. This fact is also extended to the four patients receiving corticosteroid therapy. The accumulation ofT lymphocytes in the RA SM plays an important role in the development ofinflammatory events that leads to articular damage and destruction (1) (2) (3) (4) . In the early steps ofRA, a characteristic feature is the neovascularization of the SM and the formation of perivascular lymphocyte infiltrates ( 1-4) . Additionally, the lining layer, which separates SM from the articular cavity and the SF, undergoes a significant hyperplasia which probably bears relationship to T cell infiltration (1) (2) (3) (4) . Nevertheless, the mechanisms responsible for the development of these lesions are largely unknown.
The emigration of lymphocytes from PB to SM requires their prior binding to EC. It is known that a number of ligands (ICAM-1, VCAM-1, ELAM-1, CD62/GMP1 40/PADGEM, etc.) are induced on EC surface in response to inflammatory agents (reviewed in references 5 and 6) . Recent reports indicate that initial interactions of neutrophils with EC involve the CD62-and ELAM-1-mediated rolling ofcells on the vessel wall (12, 14) . The integrins seem to participate in the next step of cell traffic, which is a reinforced adhesion, the cellular extravasation and migration into inflamed tissue which occur subsequent to leukocyte-EC selectin-mediated contacts (12, 14) . All these sequential processes have been reported for neutrophils, although the interaction ofT cells with either in vitro-activated or chronically inflamed EC in skin using an ELAM-1-mediated mechanism has also been reported (21) (22) (23) 49) .
Our results show that synovial T cells display a higher adhesiveness to ELAM-1, as compared with PB T cells. Most of such synovial T cells express a memory CD45RO+ phenotype (33, 35, 37) , a feature that has been correlated with the T cell binding to ELAM-1 (22) . The level of ELAM-1 expression by EC from inflamed synovium is reported to be similar to that found in other chronic inflammatory processes, although lower than that reported from chronic skin lesions (49) . In that latter setting, a specific T cell subset displaying ELAM-1 binding ability has been described to bear the CLA-HECA 452 antigen (49) . Whether this synovial T cell subpopulation binding ELAM-1 could also express that marker, or other synoviumrestricted antigens, requires further studies. It is noteworthy that the HECA 452 antigen has been detected on dendritic cells and EC of SM from RA (60).
In a second step ofcellular migration, leukocyte interaction with EC involves the integrin family members. These adhesion molecules would allow for a reinforced cell attachment and then the transendothelial migration (11, 12, 14) . According to current knowledge, integrin-mediated T cell binding to activated endothelium involves mostly LFA-1/ICAM-1 and VLA-4/VCAM-1 interactions (7). The expression of ICAM-1 in RA synovial tissues is known to be characteristic not only for EC but also macrophages, lining layer cells, and some lymphocytes (50, 61 (5, 6, 66, 67) . It was recently suggested that ELAM-1 could play a chemoattractant role directing the movement of leukocytes (14) . The pathological significance of an enhanced binding of SM and SF T cells to ELAM-l, that is restricted in RA synovial tissue to the EC, after their entry into SM, remains to be determined.
VLA-4 also participates in T cell binding to FN, and this interaction is enhanced upon in vitro cellular activation (29, 30, 53, 54 synovitis (2, 71) .
The pathogenesis of tissue injury in RA remains obscure.
We believe that the results presented here shed new light on the immune mechanisms responsible for tissue infiltration in this disease, highlighting the possible role of adhesion molecules in directing T cell traffic to synovial tissue, and enhancing their in situ localization, activation, and proliferation.
